纳武利尤单抗单药或联合伊匹木单抗治疗黏膜黑色素瘤的疗效与安全性:一项汇总分析
该汇总分析纳入889例接受纳武利尤单抗单药治疗的患者(其中黏膜黑色素瘤86例,皮肤黑色素瘤665例),以及纳武利尤单抗联合伊匹木单抗治疗的患者(黏膜黑色素瘤35例,皮肤黑色素瘤326例)。结果显示,黏膜黑色素瘤的客观缓解率和中位无进展生存期均低于皮肤黑色素瘤,但安全性特征在两种亚型间相似;纳武利尤单抗联合伊匹木单抗似乎比单药具有更好的疗效。
要点
- 纳武利尤单抗单药治疗黏膜黑色素瘤的客观缓解率为23.3%,皮肤黑色素瘤为40.9%。
- 纳武利尤单抗联合伊匹木单抗治疗黏膜黑色素瘤的客观缓解率为37.1%,皮肤黑色素瘤为60.4%。
- 黏膜黑色素瘤与皮肤黑色素瘤在纳武利尤单抗单药及联合治疗下的安全性特征相似。
核心结论
- 据作者所知,这是迄今为止关于抗程序性死亡蛋白-1治疗黏膜黑色素瘤的最大样本数据分析。
- 纳武利尤单抗联合伊匹木单抗似乎比单药具有更好的疗效,尽管在黏膜黑色素瘤中活性较低,但安全性特征在两种亚型间相似。
研究设计与样本
- 汇总分析,纳入889例在临床研究(包括III期试验)中接受纳武利尤单抗单药治疗的患者,其中黏膜黑色素瘤86例(10%),皮肤黑色素瘤665例(75%)。
- 同时汇总接受纳武利尤单抗联合伊匹木单抗治疗的患者数据:黏膜黑色素瘤35例,皮肤黑色素瘤326例。
主要发现
- 纳武利尤单抗单药治疗组:黏膜黑色素瘤的中位无进展生存期为3.0个月(95%CI 2.2至5.4个月),皮肤黑色素瘤为6.2个月(95%CI 5.1至7.5个月)。
- 纳武利尤单抗单药治疗组:黏膜黑色素瘤的客观缓解率为23.3%(95%CI 14.8%至33.6%),皮肤黑色素瘤为40.9%(95%CI 37.1%至44.7%)。
- 纳武利尤单抗联合伊匹木单抗治疗组:黏膜黑色素瘤的中位无进展生存期为5.9个月(95%CI 2.8个月至未达到),皮肤黑色素瘤为11.7个月(95%CI 8.9至16.7个月)。
- 纳武利尤单抗联合伊匹木单抗治疗组:黏膜黑色素瘤的客观缓解率为37.1%(95%CI 21.5%至55.1%),皮肤黑色素瘤为60.4%(95%CI 54.9%至65.8%)。
- 3级或4级治疗相关不良事件发生率:纳武利尤单抗单药治疗组黏膜黑色素瘤为8.1%,皮肤黑色素瘤为12.5%;联合治疗组黏膜黑色素瘤为40.0%,皮肤黑色素瘤为54.9%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combined with ipilimumab (a cytotoxic T-lymphocyte antigen-4 checkpoint inhibitor), have not been reported in this rare melanoma subtype. Patients and Methods Data were pooled from 889 patients who received nivolumab monotherapy in clinical studies, including phase III trials; 86 (10%) had mucosal melanoma and 665 (75%) had cutaneous melanoma. Data were also pooled for patients who received nivolumab combined with ipilimumab (n = 35, mucosal melanoma; n = 326, cutaneous melanoma). Results Among patients who received nivolumab monotherapy, median progression-free survival was 3.0 months (95% CI, 2.2 to 5.4 months) and 6.2 months (95% CI, 5.1 to 7.5 months) for mucosal and cutaneous melanoma, with objective response rates of 23.3% (95% CI, 14.8% to 33.6%) and 40.9% (95% CI, 37.1% to 44.7%), respectively. Median progression-free survival in patients treated with nivolumab combined with ipilimumab was 5.9 months (95% CI, 2.8 months to not reached) and 11.7 months (95% CI, 8.9 to 16.7 months) for mucosal and cutaneous melanoma, with objective response rates of 37.1% (95% CI, 21.5% to 55.1%) and 60.4% (95% CI, 54.9% to 65.8%), respectively. For mucosal and cutaneous melanoma, respectively, the incidence of grade 3 or 4 treatment-related adverse events was 8.1% and 12.5% for nivolumab monotherapy and 40.0% and 54.9% for combination therapy. Conclusion To our knowledge, this is the largest analysis of data for anti-programmed death-1 therapy in mucosal melanoma to date. Nivolumab combined with ipilimumab seemed to have greater efficacy than either agent alone, and although the activity was lower in mucosal melanoma, the safety profile was similar between subtypes.
引用
- D'Angelo SP, Larkin J, Sosman JA, et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J Clin Oncol. 2016. PMID: 28056206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。